ReCode Therapeutics, which is developing inhaled mRNA therapeutics for the treatment of primary ciliary dyskinesia and cystic fibrosis, has named John G. Matthews as Senior VP of Clinical Development. ReCode initiated a Phase 1 trial of its RCT1100 nebulized DNAI1 mRNA in March 2023. A pulmonologist, Matthews has extensive experience in respiratory disease research and was most recently Senior Clinical Development Leader at 23andMe; his prior experience includes stints at Aimmune Therapeutics, Roche/Genentech, GSK, and Novartis.
ReCode CEO Shehnaaz Suliman commented, “We are delighted to welcome Dr. Matthews to build and lead our clinical team. As a pulmonary and immunology drug developer with extensive experience in human genetics and inhaled drug delivery, Dr. Matthews brings a unique perspective at a formative stage of our development. I look forward to working with him as we continue to advance our pipeline of next generation precision genetic medicines for people affected by rare diseases.”
Matthews said, “With its selective organ targeting (SORT) lipid nanoparticle (LNP) technology, ReCode is pioneering a novel approach to solving one of the most significant challenges in the delivery of genetic medicines for rare diseases – an area I am incredibly passionate about. I look forward to playing a pivotal role in advancing ReCode’s lead candidates for primary ciliary dyskinesia and cystic fibrosis into the clinic this year, and ultimately, building a clinical pipeline aimed at unlocking the full potential of genetic medicines.”
Read the ReCode Therapeutics press release.
